The cancer therapy startup has closed $33.2m in series A funding from investors including AbbVie, Merck Group and Arix Bioscience.

UK-based cancer-focused biotechnology company Artios Pharma launched yesterday with $33.2m in series A capital provided by investors including pharmaceutical companies Merck Group and AbbVie.

SV Life Sciences led the round, which included life sciences company Arix Bioscience, Imperial Innovations, the investment firm affiliated with Imperial College London, which invested approximately $6.8m, CRT Pioneer Fund and European Investment Fund.

The corporates invested through their respective corporate venturing subsidiaries, Merck Ventures and AbbVie Ventures.

Artios Pharma is working on DNA damage response…